相关实验视频

Updated: Jul 28, 2025

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

对转移性细胞癌进行间歇性使用的长期使用干扰素α的长期结果:一项II期研究

Minna Kankuri-Tammilehto^1,2,3, Laura Perasto⁴, Seppo Pyrhonen^5,6

¹Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland; mikanku@utu.fi.

Anticancer research

|May 29, 2023

概括

在转移性细胞癌 (mRCC) 中,用干扰素α (IFN-α) 治疗提供长期生存益处,对反应的患者有显著的结果. 这项研究提供了对mRCC的IFN-alpha最长的随访数据,突出了其在组合疗法中的潜力.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
细胞癌研究细胞癌研究

背景情况:

干扰素-α (IFN-α) 已在转移性细胞癌 (mRCC) 中显示出生存优势.
关于在mRCC中IFN-alpha治疗的长期结果的数据有限.
了解长期影响对于评估IFN-alpha在组合疗法中至关重要,包括与免疫检查点抑制剂.

研究的目的:

评估干扰素α (IFN-α) 治疗转移性细胞癌 (mRCC) 患者的长期结果.
提供最长的随访数据可用于IFN-alpha治疗mRCC.
评估与长期IFN-alpha治疗相关的生存益处和反应模式.

主要方法:

在1994年至2002年期间,招募了117名尚未接受治疗的mRCC患者的队列,并追踪到2022年1月.
随访时间的中位数为18个月,IFN-alpha治疗的平均持续时间为11个月.
如果患者的表现状况不佳或治疗方法不可用,则患者不会接受后期治疗,如铁氨酸激酶抑制剂或贝瓦西祖马布后期进展.

主要成果:

总生存时间的中位数为19.0个月,5年生存率为16.2%,10年生存率为9.0%.
根据治疗反应观察到显著的生存差异:客观反应的中位数总生存时间为52.0个月,稳定疾病的25.0个月,进展性疾病的5.0个月 (p<0.001).
五年生存率因风险组而异:低风险患者为29%,中等风险患者为20%,高风险患者为7% (p=0.001).

结论:

长时间的IFN-alpha治疗可以导致迟到的客观反应,持久的完整反应和可接受毒性的mRCC患者的长期存活.
在mRCC多线治疗策略中,IFN-alpha仍然是一个可行的替代疗法选择.
IFN-alpha为联合治疗方法提供了一个有趣的选择,特别是与免疫检查点抑制剂结合使用.

关键词:

干扰素-阿尔法是一种干扰素.细胞癌瘤是细胞癌.

更多相关视频

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...